MATERION Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MATERION Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $5.61M | Mar 14, 2014 |
| FY2013 | Dec 31, 2012 | $6.69M | Mar 14, 2014 |
| FY2013 | Dec 31, 2011 | $9.19M | Mar 14, 2014 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.79B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.68B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $1.67B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $1.76B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $1.51B | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $339.69M | Feb 18, 2021 |
| FY2020 | Sep 25, 2020 | $287.17M | Feb 18, 2021 |
| FY2020 | Jun 26, 2020 | $271.47M | Feb 18, 2021 |
| FY2020 | Mar 27, 2020 | $277.95M | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | $280.16M | Feb 18, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $308.63M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $325.99M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $349.04M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $343.88M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $283.76M | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $55.80M | Feb 18, 2021 |
| FY2020 | Sep 25, 2020 | $45.31M | Feb 18, 2021 |
| FY2020 | Jun 26, 2020 | $46.96M | Feb 18, 2021 |
| FY2020 | Mar 27, 2020 | $44.57M | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | $54.48M | Feb 18, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $74.82M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $5.89M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $95.70M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $85.99M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $72.47M | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $8.07M | Feb 18, 2021 |
| FY2020 | Sep 25, 2020 | $5.47M | Feb 18, 2021 |
| FY2020 | Jun 26, 2020 | $5.80M | Feb 18, 2021 |
| FY2020 | Mar 27, 2020 | ($3.88M) | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | $14.35M | Feb 18, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $109.80M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $47.22M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $136.44M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $119.76M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $77.11M | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $6.83M | Feb 18, 2021 |
| FY2020 | Sep 25, 2020 | ($616.0K) | Feb 18, 2021 |
| FY2020 | Jun 26, 2020 | $7.57M | Feb 18, 2021 |
| FY2020 | Mar 27, 2020 | ($5.57M) | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | $16.05M | Feb 18, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.94M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $29.03M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $27.54M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $28.98M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $26.58M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $20.28M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $18.27M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $15.19M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $13.98M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $12.80M | Feb 14, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $143.06M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $145.59M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $157.91M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $169.34M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $163.78M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $133.96M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $147.16M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $153.49M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $144.28M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $128.97M | Feb 14, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $103.24M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $87.82M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $144.41M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $115.96M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $90.24M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $101.06M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $99.22M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $76.37M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $67.80M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $68.18M | Feb 14, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $68.65M | Feb 19, 2025 |
| FY2024 | Dec 31, 2023 | $110.55M | Feb 19, 2025 |
| FY2024 | Dec 31, 2022 | $77.61M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $102.91M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $67.27M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $24.25M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $27.70M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $27.52M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $27.18M | Feb 14, 2019 |
| FY2017 | Dec 31, 2015 | $29.51M | Feb 15, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.80B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.70B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $1.76B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $1.69B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $1.61B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $1.06B | Feb 17, 2022 |
| FY2021 | Dec 31, 2019 | $898.43M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $843.31M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $791.08M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $741.30M | Feb 14, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $943.28M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $868.88M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $885.05M | Feb 12, 2026 |
| FY2025 | Dec 31, 2022 | $799.99M | Feb 12, 2026 |
| FY2024 | Dec 31, 2021 | $720.44M | Feb 19, 2025 |
| FY2023 | Dec 31, 2020 | $655.63M | Feb 15, 2024 |
| FY2022 | Dec 31, 2019 | $645.74M | Feb 16, 2023 |
| FY2021 | Dec 31, 2018 | $586.24M | Feb 17, 2022 |
| FY2020 | Dec 31, 2017 | $527.12M | Feb 18, 2021 |
| FY2019 | Dec 31, 2016 | $494.09M | Feb 13, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $280.66M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $263.74M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $320.87M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $319.50M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $318.62M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $144.92M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $79.01M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $90.66M | Feb 18, 2021 |
| FY2018 | Dec 31, 2017 | $90.68M | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $86.95M | Feb 15, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $912.36M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $849.11M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $854.33M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $769.42M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $693.76M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $631.06M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $624.95M | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $548.37M | Feb 13, 2020 |
| FY2018 | Jan 1, 2018 | $536.54M | Feb 14, 2019 |
| FY2018 | Dec 31, 2017 | $536.12M | Feb 14, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.68M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $16.71M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $13.29M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $13.10M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $14.46M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $25.88M | Feb 17, 2022 |
| FY2021 | Dec 31, 2019 | $125.01M | Feb 17, 2022 |
| FY2021 | Dec 31, 2018 | $70.65M | Feb 17, 2022 |
| FY2020 | Dec 31, 2017 | $41.84M | Feb 18, 2021 |
| FY2019 | Dec 31, 2016 | $31.46M | Feb 13, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $460.64M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $443.90M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $428.99M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $435.79M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $454.55M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $38.48M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $2.22M | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $3.04M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $3.82M | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $4.62M | Feb 15, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | 4 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | 4 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Sep 25, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Jun 26, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Mar 27, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 18, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | 4 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | 4 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Sep 25, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Jun 26, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Mar 27, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 18, 2021 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.51M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $11.09M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $10.62M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $10.16M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $9.70M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $9.26M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $8.86M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $8.39M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $7.91M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $7.50M | Feb 14, 2019 |